Journal of Immunology Research / 2012 / Article / Tab 2

Research Article

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy

Table 2

Functional characteristics of intracellular processes in CD4+ and CD8+ cells following PHA activation in ankylosing spondylitis patients before and during infliximab (IFX) therapy.

ParameterHealthy controls Before IFX therapy Week 2 after IFX therapy Week 6 after IFX therapy

Cytoplasmic Ca2+

CD4+AUC (U)63.24 [58.00–107.9]82.43 [64.22–255.8]93.57 [56.89–201.0]96.21 [87.13–158.10]
Max (rpv)1.156 [1.132–1.256]1.268 [1.174–1.623]1.321 [1.149–1.477]1.254 [1.216–1.420]
(s)258.4 [192.1–283.5]527.5 [327.9 595.3]*471.1 [288.2–594.3]*594.7 [290.5–595.5]*
CD8+AUC (U)48.76 [38.53–93.22]88.52 [54.65–327.8]104.8 [42.14–180.8]81.55 [58.51–407.1]
Max (rpv)1.139 [1.089–1.262]1.247 [1.124–1.852]1.318 [1.120–1.434]1.220 [1.125–1.819]
(s)228.6 [162.1–593.2]594.3 [294.6–595.6]*594.4 [422.9–596.1]*282.7 [232.9–531.0]

Mitochondrial Ca2+

CD4+AUC (U)61.64 [37.97–94.43]66.00 [41.55–95.52]64.87 [42.90–105.4]67.60 [49.29–104.2]
Max (rpv)1.194 [1.121–1.272]1.207 [1.103–1.241]1.149 [1.114–1.281]1.172 [1.159–1.266]
(s)594.0 [211.9–594.9]593.3 [384.7–595.3]595.2 [593.0–596.2]595.1 [386.6–596.4]
CD8+AUC (U)106.9 [71.64–144.5]87.79 [62.47–101.4]71.31 [53.46–175.0]118.8 [67.55–249.9]
Max (rpv)1.250 [1.152–1.404]1.187 [1.130–1.217]1.154 [1.131–1.400]1.259 [1.143–1.539]
(s)144.2 [121.6–160.6]577.1 [167.8–594.2]*468.8 [165.3–594.7]*198.7 [169.8–248.4]

Nitric oxide production

CD4+AUC (U)3.318 [−8.315–18.84]47.76 [1.727–97.18]*22.20 [−8.903–37.95]−3.055 [−13.24–9.005]#
Max (rpv)1.013 [1.000–1.043]1.113 [1.011–1.282]*1.046 [1.000–1.081]1.001 [1.000–1.034]#
(s)198.7 [34.55–321.8]594.3 [228.2–594.8]*331.2 [0.000–556.5]107.9 [0.000–252.5]#
CD8+AUC (U)−9.481 [−19.97–24.30]41.31 [6.068–109.8]*9.641 [−11.20–29.92]−11.80 [−29.93–4.094]#
Max (rpv)1.003 [1.000–1.051]1.099 [1.011–1.330]*1.025 [1.001–1.078]1.000 [1.000–1.001]#
(s)51.08 [0.000–185.2]594.2 [185.2–594.8]*289.1 [54.03–553.5]0.001 [0.000–130.5]#

Superoxide generation

CD4+AUC (U)79.27 [64.68–88.90]75.65 [70.70–92.61]82.64 [58.40–96.68]70.99 [56.09–83.99]
CD8+AUC (U)73.15 [62.21–80.33]74.97 [61.28–98.75]83.87 [58.13–90.74]60.34 [51.38–85.42]

Data are expressed as median [interquartile range] *versus control ; #versus before IFX therapy ; AUC: area under the curve, Max: maximum value, : time to reach maximum.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.